Lupus Nephritis Clinical Trials, Lupus Nephritis: Diagnosis and Management, Glomerulonephritis: Caus скачать в хорошем качестве

Lupus Nephritis Clinical Trials, Lupus Nephritis: Diagnosis and Management, Glomerulonephritis: Caus

A 28-year-old pregnant woman with longstanding systemic lupus erythematosus and a history of autoimmune disease presents at 28 weeks gestation with new-onset leg edema, persistently elevated blood pressure, and concerning laboratory findings, including abnormal renal indices and low complement levels. How should you approach the diagnostic workup to distinguish between overlapping causes of kidney dysfunction and hypertension in this complex clinical scenario? What clinical features and tests can guide your reasoning? VIDEO INFO Category: Lupus Nephritis Clinical Trials, Lupus Nephritis: Diagnosis and Management, Glomerulonephritis: Causes, Diagnosis, and Management, Nephrology: Kidney Disease Diagnosis and Management Difficulty: Expert - Expert level - For those seeking deep understanding Question Type: Differential Testing Case Type: Pregnant Patient Explore more ways to learn on this and other topics by going to https://endlessmedical.academy/auth?h... QUESTION A 28-year-old pregnant woman (G1P0, 28 weeks) with systemic lupus erythematosus presents for urgent assessment of new edema and rising home blood pressures. She reports normal fetal movements. She lives with family, does not smoke, and denies alcohol or illicit drug use. Past history includes Hashimoto thyroiditis and microscopic polyangiitis in remission; there is no prior kidney biopsy.... OPTIONS A. Obtain a serum sFlt-1/PlGF ratio with a validated assay; a high ratio supports preeclampsia, whereas a non-elevated ratio with active sediment favors lupus flare. B. Order trial screening for belimumab or voclosporin because pregnancy does not affect eligibility and centralized review will classify the renal process and triage enrollment. C. Rely on urine dipstick protein for two weeks without microscopy, since the degree of proteinuria alone separates preeclampsia from lupus flare. D. Use noninvasive fetal monitoring only, because normal fetal heart patterns exclude preeclampsia as a cause of maternal hypertension and proteinuria in the mother. CORRECT ANSWER A. Obtain a serum sFlt-1/PlGF ratio with a validated assay; a high ratio supports preeclampsia, whereas a non-elevated ratio with active sediment favors lupus flare. EXPLANATION In a 28-week pregnancy with SLE, the most actionable discriminator between preeclampsia and lupus nephritis flare is the angiogenic balance measured by the serum sFlt-1/PlGF ratio. Preeclampsia is characterized by placental antiangiogenic excess (high sFlt-1 and low PlGF), producing a high ratio; lupus flare typically lacks this signature. Here, superimposed hypertension, proteinuria, active urine sediment with dysmorphic RBCs and red cell casts, rising anti-double-stranded DNA, and hypocomplementemia point toward an SLE flare, but preeclampsia remains plausible at 28 weeks. A validated sFlt-1/PlGF assay provides rapid, pregnancy-specific discrimination to align maternal therapy and monitoring. Enrollment into standard adult LN drug trials is not appropriate during pregnancy; contemporary belimumab and voclosporin trials excluded pregnant participants. Urine dipstick alone cannot distinguish entities, and fetal monitoring cannot diagnose or exclude maternal preeclampsia. In summary, the correct answer is to obtain a validated serum sFlt-1/PlGF ratio now; a high ratio supports preeclampsia, whereas a non-elevated ratio with active sediment favors lupus flare. Primary teaching point: sFlt-1/PlGF is a pregnancy-specific biomarker that differentiates preeclampsia from LN flare.... Further reading: Links to sources are provided for optional further reading only. The questions and explanations are independently authored and do not reproduce or adapt any specific third-party text or content. --------------------------------------------------- Our cases and questions come from the https://EndlessMedical.Academy quiz engine - multi-model platform. Each question and explanation is forged by consensus between multiple top AI models (i.e. Open AI GPT, Claude, Grok, etc.), with automated web searches for the latest research and verified references. Calculations (e.g. eGFR, dosages) are checked via code execution to eliminate errors, and all references are reviewed by several AIs to minimize hallucinations. Important note: This material is entirely AI-generated and has not been verified by human experts; despite stringent consensus checks, perfect accuracy cannot be guaranteed. Exercise caution - always corroborate the content with trusted references or qualified professionals, and never apply information from this content to patient care or clinical decisions without independent verification. Clinicians already rely on AI and online tools - myself included - so treat this content as an additional focused aid, not a replacement for proper medical education. Visit https://endlessmedical.academy for more AI-supported resources and cases. This material can not be treated as medical advice. May conta...